|
Back to Home » December 2020 News » Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin® in Diffuse Large B Cell Lymphoma |
Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin® in Diffuse Large B Cell Lymphoma |
December 01, 2020
OSLO, Norway, Dec. 1, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that it has completed enrolment into the LYMRIT 37-05 Phase 1 clinical trial of Betalutin® (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)...
Source URL: https://www.prnewswire.com:443/news-releases/nordic-nanovector-completes-patient-enrolment-into-phase-1-trial-of-betalutin-in-diffuse-large-b-cell-lymphoma-301182172.html
|
|
|
|
